AlphAIalphai — Financial news for AI agents
GuruFocusMAR 94 min read$CHRS

Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect

Coherus BioSciences (CHRS) is expected to report a significant decline in EPS and revenue for Q4, with analysts forecasting -$0.31 EPS and $14.09 million in revenue. The biotechnology company, focusing on oncology, shows financial distress indicators like a negative Altman Z-Score and declining revenue growth. Despite the financial challenges, its strategic focus on expanding the oncology pipeline offers potential long-term growth, though near-term risks remain significant.

Original reporting
GuruFocus · GuruFocus News
Published Mar 9, 2026, 6:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 9, 2026, 7:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$CHRS
Bearish
medium confidence
Mentioned
$CHRS
alphai data visualization · based on GuruFocus
Decision brief

The 30-second read

$CHRSBearishLow
01

Why it matters

The upcoming earnings report is expected to be weak, which could lead to short-term stock decline, but strategic pipeline expansion might provide long-term growth potential.

02

Market read

The news is highly relevant to biotech investors, especially those holding or considering exposure to CHRS, due to imminent earnings and financial health concerns.

03

What to watch

Potential positive news on pipeline progress or partnership announcements could offset financial concerns.

Timing: short-term (next 1-3 months)

Background

Coherus BioSciences is a biotech company focusing on oncology therapeutics, currently facing financial distress with declining earnings and revenue.

Company-level read

Ticker impact

$CHRSBearishMedium confidence
Context

Primary focus of the news, significant impact expected due to financial distress indicators and earnings forecast.

Expected impact

Potential short-term decline of 10-15% due to earnings miss and financial distress, with possible stabilization if pipeline developments prove successful.

Evidence & confidence

The forecasted earnings and revenue declines, combined with negative financial indicators, suggest bearish short-term movement. However, strategic growth initiatives could mitigate downside risks over the longer term.

Market effects

Sector

Potential negative impact on biotech and oncology sectors due to company-specific issues.

Regional

Limited regional impact; primarily affects US biotech sector.

Global

Minimal; company-specific news with limited global market influence.

Counterpoint

What could challenge this read

If the oncology pipeline expansion yields positive results, the stock could rebound, offering a buying opportunity at current levels.

Key entities

  • Company
    Coherus BioSciences

    A biotechnology company specializing in oncology therapeutics.

  • Product Development
    Oncology Pipeline

    The company's strategic focus area for future growth.

Read at source← All news

Related articles

AUG 13
$CHRSMedAI 8/10

Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.

fool.com6 min
AUG 7
$CHRSMed

Coherus Oncology Q2 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) reported Q2 updates on tagmokitug and LOQTORZI during an earnings call. It said preliminary head and neck response and biomarker findings are based on limited patients, with formal disclosure expected in October. LOQTORZI net sales were $13.6M, up 15% sequentially. Full-year 2026 LOQTORZI revenue guidance is $57M to $62M; 2026 operating expenses $170M to $175M.

yahoo.com6 min
AUG 5
$CHRSMed

Coherus Oncology, Inc. (CHRS): Results of Operations and Financial Condition

Coherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 chrs-20260805xex99d1.htm EX-99.1 Exhibit 99.1 ​ Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update ​ – LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – ​ – Clinical data continue to mature across programs with

SEC EDGAR 8-K6 min
AUG 18
$RKLBMedAI 8/10

Rocket Lab Now Prime and Bus Supplier in GEO: Viasat Selects Lightning-GEO for Anti-Jam Satellite

Rocket Lab was selected by Viasat to supply the satellite bus for Viasat’s U.S. Space Force anti-jam Protected Tactical SATCOM-Global (PTS-G) Swarm 1 spacecraft, using Rocket Lab’s Lightning-GEO platform. Viasat will integrate, operate, and lead the prime role; Rocket Lab builds the bus. The Swarm 1 delivery order totals about $437.7M across contractors; terms were not disclosed.

techtimes.com7 min
AUG 17
$LHXMed

L3Harris ousts CEO Kubasik over conduct violation

L3Harris Technologies said CEO Christopher Kubasik stepped down after a board investigation found misconduct and the company entered a separation agreement. The company did not disclose details, saying the conduct was unrelated to financial reporting or operations. Sam Mehta was named successor. Reuters reported no severance, but he can keep vested options. LHX shares fell.

foxbusiness.com3 min